ArticleSignal transduction and targeted therapy2022
SARS-CoV-2 variant Omicron: currently the most complete "escapee" from neutralization by antibodies and vaccines.
Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.Science translational medicine · 2022Trial
- Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.Emerging microbes & infections · 2026Article
- Building a coronavirus disease 2019 healthcare registry in an evolving pandemic.Scientific reports · 2025Article
- Monoclonal antibodies against human TMPRSS2 prevent infection by any SARS-CoV-2 variant.iScience · 2025Article
- Review
- Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.Infectious diseases and therapy · 2024Review
- Humoral Immune Response to SARS-CoV-2 Spike Protein Receptor-Binding Motif Linear Epitopes.Vaccines · 2024Article
- Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China.Human vaccines & immunotherapeutics · 2023Article
- Delta SARS-CoV-2 s2m Structure, Dynamics, and Entropy: Consequences of the G15U Mutation.ACS physical chemistry Au · 2023Article
- Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19.Human vaccines & immunotherapeutics · 2023Article
- The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China.BMC public health · 2023Article
- Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.Journal of medical virology · 2023Article
- Structural, Dynamical, and Entropic Differences between SARS-CoV and SARS-CoV-2 s2m Elements Using Molecular Dynamics Simulations.ACS physical chemistry Au · 2023Article
- Neuroprotective potentials of ferulic acid against intracerebral hemorrhage COVID-19 through using network pharmacology approach and molecular docking analysis.Current research in toxicology · 2023Article
- An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.Science China. Life sciences · 2023Article
- Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai.Journal of medical virology · 2023Article
- Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians.Annals of internal medicine · 2023Review
- Review
- Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events.BMC infectious diseases · 2022Review
- Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions.MedComm · 2022Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.